SCHEMBL5756059

SCHEMBL5756059

CSCC[C@@H](NS(=O)(=O)c1ccc2nc(SCC3CCCCC3)sc2c1)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.50
LMNA P02545 3/20 0.49
ALDH1A1 P00352 2/20 0.49
RAB9A P51151 2/20 0.49
HTT P42858 2/20 0.49
HSP90AA1 P07900 1/20 0.49
HPGD P15428 1/20 0.49
TSHR P16473 1/20 0.49
MEN1 O00255 1/20 0.48
CYP2C9 P11712 1/20 0.48
KMT2A Q03164 1/20 0.48
KDM4E B2RXH2 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
POLB P06746 1/20 0.48
PKM P14618 1/20 0.40
ALOX15 P16050 1/20 0.40
MAPK1 P28482 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
CLK1 P49759 1/20 0.39
MMP2 P08253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5755594 0.92 ALDH1A1 (0.48) RXFP1LMNAALDH1A1RAB9AHTT
SCHEMBL5755972 0.86 POLB (0.48) LMNAALDH1A1HTTHSP90AA1HPGD
SCHEMBL5757798 0.86 LMNA (0.52) LMNAALDH1A1HTTHSP90AA1HPGD
SCHEMBL5757831 0.84 SMN1; SMN2 (0.51) LMNAALDH1A1HTTHSP90AA1HPGD
SCHEMBL5755120 0.83 RAB9A (0.52) RXFP1LMNARAB9AMEN1CYP2C9
SCHEMBL5754188 0.82 RAB9A (0.52) RXFP1LMNARAB9AMEN1CYP2C9
SCHEMBL5755212 0.82 ALDH1A1 (0.51) LMNAALDH1A1HTTHSP90AA1HPGD
SCHEMBL5755993 0.80 MMP2 (0.48) LMNAALDH1A1HTTHSP90AA1HPGD
SCHEMBL5756642 0.80 SMN1; SMN2 (0.50) LMNAALDH1A1HTTHSP90AA1HPGD
SCHEMBL7221233 0.77 SMN1; SMN2 (0.49) LMNAALDH1A1HTTHSP90AA1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1208092-B1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2006-06-21 EP disclosed
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 US disclosed
EP-1208092-A4 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2003-01-02 EP disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 US disclosed
EP-1208092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-05-29 EP disclosed
WO-2001077092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 RXFP1 2743/4885LMNA 1839/4885ALDH1A1 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.